drugset
drugset / Trial / NCT04695847

M1231 in Participants With Solid Tumors

NCT04695847 ↗

Phase 1 Completed 23 enrolled EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is to establish a safe and tolerable dose and to investigate pharmacokinetics and the first clinical efficacy signals of M1231 as a single agent in participants with solid tumors (Part 1) and with metastatic Non-small Cell Lung Cancer (NSCLC) and esophageal squamous cell carcinoma (Part 2). Dose escalation will be followed by the dose expansion once the maximum tolerated dose (MTD) or recommended dose for Expansion (RDE) has been defined.

Timeline

Start
2021-01-13
Primary completion
2023-06-23
Completion
2023-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject M1231 Unknown — —

Indications

esophageal cancer metastatic neoplasm non-small cell lung carcinoma